Cargando…

Discovery of novel JAK1 inhibitors through combining machine learning, structure-based pharmacophore modeling and bio-evaluation

BACKGROUND: Janus kinase 1 (JAK1) plays a critical role in most cytokine-mediated inflammatory, autoimmune responses and various cancers via the JAK/STAT signaling pathway. Inhibition of JAK1 is therefore an attractive therapeutic strategy for several diseases. Recently, high-performance machine lea...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Zixiao, Sun, Lili, Xu, Yu, Liang, Peida, Xu, Kaiyan, Huang, Jing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10464202/
https://www.ncbi.nlm.nih.gov/pubmed/37641144
http://dx.doi.org/10.1186/s12967-023-04443-6
_version_ 1785098414517649408
author Wang, Zixiao
Sun, Lili
Xu, Yu
Liang, Peida
Xu, Kaiyan
Huang, Jing
author_facet Wang, Zixiao
Sun, Lili
Xu, Yu
Liang, Peida
Xu, Kaiyan
Huang, Jing
author_sort Wang, Zixiao
collection PubMed
description BACKGROUND: Janus kinase 1 (JAK1) plays a critical role in most cytokine-mediated inflammatory, autoimmune responses and various cancers via the JAK/STAT signaling pathway. Inhibition of JAK1 is therefore an attractive therapeutic strategy for several diseases. Recently, high-performance machine learning techniques have been increasingly applied in virtual screening to develop new kinase inhibitors. Our study aimed to develop a novel layered virtual screening method based on machine learning (ML) and pharmacophore models to identify the potential JAK1 inhibitors. METHODS: Firstly, we constructed a high-quality dataset comprising 3834 JAK1 inhibitors and 12,230 decoys, followed by establishing a series of classification models based on a combination of three molecular descriptors and six ML algorithms. To further screen potential compounds, we constructed several pharmacophore models based on Hiphop and receptor-ligand algorithms. We then used molecular docking to filter the recognized compounds. Finally, the binding stability and enzyme inhibition activity of the identified compounds were assessed by molecular dynamics (MD) simulations and in vitro enzyme activity tests. RESULTS: The best performance ML model DNN-ECFP4 and two pharmacophore models Hiphop3 and 6TPF 08 were utilized to screen the ZINC database. A total of 13 potentially active compounds were screened and the MD results demonstrated that all of the above molecules could bind with JAK1 stably in dynamic conditions. Among the shortlisted compounds, the four purchasable compounds demonstrated significant kinase inhibition activity, with Z-10 being the most active (IC(50) = 194.9 nM). CONCLUSION: The current study provides an efficient and accurate integrated model. The hit compounds were promising candidates for the further development of novel JAK1 inhibitors. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12967-023-04443-6.
format Online
Article
Text
id pubmed-10464202
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-104642022023-08-30 Discovery of novel JAK1 inhibitors through combining machine learning, structure-based pharmacophore modeling and bio-evaluation Wang, Zixiao Sun, Lili Xu, Yu Liang, Peida Xu, Kaiyan Huang, Jing J Transl Med Research BACKGROUND: Janus kinase 1 (JAK1) plays a critical role in most cytokine-mediated inflammatory, autoimmune responses and various cancers via the JAK/STAT signaling pathway. Inhibition of JAK1 is therefore an attractive therapeutic strategy for several diseases. Recently, high-performance machine learning techniques have been increasingly applied in virtual screening to develop new kinase inhibitors. Our study aimed to develop a novel layered virtual screening method based on machine learning (ML) and pharmacophore models to identify the potential JAK1 inhibitors. METHODS: Firstly, we constructed a high-quality dataset comprising 3834 JAK1 inhibitors and 12,230 decoys, followed by establishing a series of classification models based on a combination of three molecular descriptors and six ML algorithms. To further screen potential compounds, we constructed several pharmacophore models based on Hiphop and receptor-ligand algorithms. We then used molecular docking to filter the recognized compounds. Finally, the binding stability and enzyme inhibition activity of the identified compounds were assessed by molecular dynamics (MD) simulations and in vitro enzyme activity tests. RESULTS: The best performance ML model DNN-ECFP4 and two pharmacophore models Hiphop3 and 6TPF 08 were utilized to screen the ZINC database. A total of 13 potentially active compounds were screened and the MD results demonstrated that all of the above molecules could bind with JAK1 stably in dynamic conditions. Among the shortlisted compounds, the four purchasable compounds demonstrated significant kinase inhibition activity, with Z-10 being the most active (IC(50) = 194.9 nM). CONCLUSION: The current study provides an efficient and accurate integrated model. The hit compounds were promising candidates for the further development of novel JAK1 inhibitors. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12967-023-04443-6. BioMed Central 2023-08-28 /pmc/articles/PMC10464202/ /pubmed/37641144 http://dx.doi.org/10.1186/s12967-023-04443-6 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Wang, Zixiao
Sun, Lili
Xu, Yu
Liang, Peida
Xu, Kaiyan
Huang, Jing
Discovery of novel JAK1 inhibitors through combining machine learning, structure-based pharmacophore modeling and bio-evaluation
title Discovery of novel JAK1 inhibitors through combining machine learning, structure-based pharmacophore modeling and bio-evaluation
title_full Discovery of novel JAK1 inhibitors through combining machine learning, structure-based pharmacophore modeling and bio-evaluation
title_fullStr Discovery of novel JAK1 inhibitors through combining machine learning, structure-based pharmacophore modeling and bio-evaluation
title_full_unstemmed Discovery of novel JAK1 inhibitors through combining machine learning, structure-based pharmacophore modeling and bio-evaluation
title_short Discovery of novel JAK1 inhibitors through combining machine learning, structure-based pharmacophore modeling and bio-evaluation
title_sort discovery of novel jak1 inhibitors through combining machine learning, structure-based pharmacophore modeling and bio-evaluation
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10464202/
https://www.ncbi.nlm.nih.gov/pubmed/37641144
http://dx.doi.org/10.1186/s12967-023-04443-6
work_keys_str_mv AT wangzixiao discoveryofnoveljak1inhibitorsthroughcombiningmachinelearningstructurebasedpharmacophoremodelingandbioevaluation
AT sunlili discoveryofnoveljak1inhibitorsthroughcombiningmachinelearningstructurebasedpharmacophoremodelingandbioevaluation
AT xuyu discoveryofnoveljak1inhibitorsthroughcombiningmachinelearningstructurebasedpharmacophoremodelingandbioevaluation
AT liangpeida discoveryofnoveljak1inhibitorsthroughcombiningmachinelearningstructurebasedpharmacophoremodelingandbioevaluation
AT xukaiyan discoveryofnoveljak1inhibitorsthroughcombiningmachinelearningstructurebasedpharmacophoremodelingandbioevaluation
AT huangjing discoveryofnoveljak1inhibitorsthroughcombiningmachinelearningstructurebasedpharmacophoremodelingandbioevaluation